Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.59 |
| ▸ | LCK | P06239 | 7/20 | 0.56 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.51 |
| ▸ | IDH1 | O75874 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27850412 | 0.87 | IDH1 (0.51) | HTR7LCKPLK1JAK2JAK3 | |
| SCHEMBL27850423 | 0.84 | HTR7 (0.52) | HTR7JAK2JAK3ADRA1DHTR2C | |
| SCHEMBL4644412 | 0.83 | HRH4 (0.49) | HTR7LCK | |
| SCHEMBL14629467 | 0.82 | HTR7 (0.57) | HTR7LCKPLK1JAK2JAK3 | |
| SCHEMBL7016449 | 0.81 | IDH1 (0.55) | HTR7ADRA1DADRA1AADRA1BIDH1 | |
| SCHEMBL28120957 | 0.81 | HTR7 (0.57) | HTR7LCKPLK1JAK2JAK3 | |
| SCHEMBL17076676 | 0.81 | MAPK14 (0.56) | HTR7LCKPLK1JAK2JAK3 | |
| SCHEMBL17076677 | 0.81 | MAPK14 (0.56) | HTR7LCKPLK1JAK2JAK3 | |
| SCHEMBL1600112 | 0.81 | HTR7 (0.56) | HTR7LCKPLK1JAK2JAK3 | |
| SCHEMBL10271508 | 0.78 | HTR7 (0.56) | HTR7LCKPLK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |